Screening for bladder cancer: A perspective

World Journal of Urology

Volumn 26, Issue 1, 2008, Pages 13-18

  Lotan, Yair ^a   Svatek, Robert S ^b   Malats, Núria ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Bladder cancer screening; Cost effectiveness; Target population

Indexed keywords

BLADDER TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH SERVICE; HUMAN; MASS SCREENING; METHODOLOGY; MORBIDITY; ORGANIZATION AND MANAGEMENT; REVIEW; SURVIVAL RATE; UNITED STATES;

COST-BENEFIT ANALYSIS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MASS SCREENING; MORBIDITY; SURVIVAL RATE; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 39349112505     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0223-2     Document Type: Review

References (33)

1. Britton JP, Dowell AC, Whelan P, Harris CM (1992) A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 148(3):788-790
2. Messing EM, Young TB, Hunt VB, Newton MA, Bram LL, Vaillancourt A, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD (1995) Hematuria home screening: Repeat testing results. J Urol 154(1):57-61
3. NCI (2007) "NCI cancer screening overview." http://www.cancer.gov/cancerinfo/pdq/screening/overview. Accessed 26 Aug 2007
4. Beinfeld MT, Wittenberg E, Gazelle GS (2005) Cost-effectiveness of whole-body CT screening. Radiology 234(2):415-422
5. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
6. Silverman DT, Hartge P, Morrison AS, Devesa SS (1992) Epidemiology of bladder cancer. Hematol Oncol Clin North Am 6(1):1-30
7. Zeegers MP, Tan FE, Dorant E, van den Brandt PA (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. Cancer 89(3):630-639
8. Samanic C, Kogevinas M, Dosemeci M, Malats N, Real FX, Garcia-Closas M, Serra C, Carrato A, Garcia-Closas R, Sala M et al (2006) Smoking and bladder cancer in Spain: Effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 15(7):1348-1354
9. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R et al (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish bladder cancer study and meta-analyses. Lancet 366(9486):649-659
10. Wu XR (2005) Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5(9):713-725
11. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21(18):1315-1330
12. American College of Surgeons. Commission on Cancer National Cancer Database. http://www.facs.org/cancer/ncdb/index.html. Accessed 7 Sep 2005
13. Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission
14. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19(3):666-675
15. Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23(27):6533-6539
16. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD (1995) Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45(3):387-396 discussion 396-397
17. Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, Wegenke JD, Stephenson L, Gee J, Feng C (2006) Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107(9):2173-2179
18. Mayfield MP, Whelan P (1998) Bladder tumours detected on screening: results at 7 years. Br J Urol 82(6):825-828
19. Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, Duffy S, Ritchie G, Kleijnen J, Westwood M. Diagnostic tests and algorithms used in the investigation of haematuria: Systematic reviews and economic evaluation. Health Technol Assess 10(18):iii-iv, xi-259
20. Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 61(1):109-118
21. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, Jansz K, Bridge JA, Johansson SL, Persons DL et al (2006) Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176(1):44-47
22. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810-816
23. Benoit RM, Gronberg H, Naslund MJ (2001) A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer Prostatic Dis 4(3):138-145
24. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN (2002) Screening for colorectal cancer in adults at average risk: A summary of the evidence for the U.S. preventive services task force. Ann Intern Med 137(2):132-141
25. Redaelli A, Cranor CW, Okano GJ, Reese PR (2003) Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 21(17):1213-1238
26. Lindfors KK, Rosenquist CJ (1995) The cost-effectiveness of mammographic screening strategies. JAMA 274(11):881-884
27. Shen Y, Parmigiani G (2005) A model-based comparison of breast cancer screening strategies: Mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev 14(2):529-532
28. Peto J, Gilham C, Fletcher O, Matthews FE (2004) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364(9430):249-256
29. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A et al (1998) Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized trial with palliative end points. J Clin Oncol 16(6):2272-2279
30. Krahn MD, Coombs A, Levy IG (1999) Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen. CMAJ 160(1):49-57
31. Lotan Y, Svatek RS, Sagalowsky AI (2006) Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer 107(5):982-990
32. Svatek RS, Sagalowsky AI, Lotan Y (2006) Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis. Urol Oncol 24(4):338-343
33. Mehlman MJ (2004) Predictive genetic testing in urology: Ethical and social issues. World J Urol 21(6):433-437